Pure Peptides Lab Ltd is registered in England & Wales, company number 16876166 .
Email us now:
Compound deep-dive
TB-500 explained: the Thymosin Beta-4 fragment.
A synthetic peptide built around the conserved actin-binding motif of Thymosin Beta-4. Forty years of literature from Goldstein, Kleinman and the wider thymosin field. The compound that most suppliers leave fuzzy about whether you’re actually getting a fragment or the full 43-residue protein.
TB-500 Research Overview
TL;DR. TB-500 is the research-peptide market name for a synthetic peptide derived from the naturally occurring protein Thymosin Beta-4 (TB4).
The peptide commonly supplied for research is a short synthetic fragment built around the conserved LKKTET actin-binding motif rather than the complete 43-amino-acid Thymosin Beta-4 protein.
Research Background
Both the synthetic TB-500 fragment and the full-length Thymosin Beta-4 protein engage the same actin-binding pharmacology in published preclinical research. However, they differ in chemistry, molecular composition, manufacturing process, and synthesis cost.
Laboratory Verification
A high-quality research-grade TB-500 batch should demonstrate:
- Clean single-peak HPLC chromatogram with 99%+ purity.
- Mass spectrometry confirmation matching the stated peptide sequence.
- Uniform porous white lyophilized cake.
- A Certificate of Analysis (COA) listing the complete peptide sequence rather than only the trade name.
Research Use Only.
This material is intended exclusively for laboratory and scientific research. It is not intended for human consumption, diagnosis, treatment, or prevention of any disease.
What TB-500 actually is
The molecule sold across the research-peptide market under the trade name TB-500 is a synthetic peptide derived from a much larger naturally occurring protein, Thymosin Beta-4. The parent protein is one of the most abundant intracellular proteins in mammalian tissue and was characterised over decades of work by Allan Goldstein, Hynda Kleinman and collaborators at George Washington University and the National Institutes of Health.
Native Thymosin Beta-4 is 43 amino acids long with an average molecular weight of around 4963 g/mol. The molecule’s pharmacology is dominated by a small conserved sequence near the N-terminus, LKKTET (Leu-Lys-Lys-Thr-Glu-Thr), which is the actin-binding motif. This motif is shared across the wider beta-thymosin family and is the structural reason these molecules regulate the actin cytoskeleton in the first place.
The market shorthand ‘TB-500’ covers two related but distinct preparations. The first is a short synthetic fragment built around the LKKTET motif and the surrounding N-terminal residues, typically around 17 amino acids long. The second is the full 43-residue Thymosin Beta-4 protein produced synthetically or recombinantly. Both are sold under the same trade name across the market, which is the single most common point of confusion when buying.
| Trade name | TB-500 |
| Parent protein | Thymosin Beta-4 (Tβ4) |
| Parent length | 43 amino acids |
| Parent average MW | ~4963 g/mol |
| Common fragment length | ~17 amino acids (varies by supplier) |
| Common fragment MW | ~1700-1800 g/mol (depends on exact sequence) |
| Key motif | LKKTET (Leu-Lys-Lys-Thr-Glu-Thr), the actin-binding sequence |
| Lyophilised stability | 24+ months at 2–8 °C, sealed and protected from light |
| Reconstituted stability | Typically several weeks under refrigeration; consult method-specific literature |
The fragment versus full-protein chemistry question
The most common ambiguity in this market.
Two completely different molecules get sold under exactly the same name. Vial A might contain a 17-residue actin-binding fragment with an average molecular weight around 1700 g/mol. Vial B might contain the full 43-residue Thymosin Beta-4 protein at around 4963 g/mol.
Both are labelled TB-500. Both will produce the relevant actin-binding pharmacology in cell-based assays. But they are not the same compound chemically, they are not the same synthesis cost, and they will not produce the same mass-spectrometry signal.
The bench scientist’s defence is simple: require the COA to state the sequence, not just the trade name. If the certificate of analysis quotes the molecular weight of the molecule in the vial, you can immediately tell which preparation you have.
If it quotes only a percentage purity and a trade name, that’s ambiguity that benefits the seller — not you.
The discovery and the thymosin literature
The thymosin family came out of decades of immunology research at the National Institutes of Health and George Washington University, where Allan Goldstein and his collaborators first isolated and characterised the thymic hormones in the 1960s and 1970s. The beta-thymosins, including Tβ4, were identified as a distinct subfamily over subsequent decades, with the actin-binding role established through a long series of biochemical and structural studies.
The published preclinical literature now covers a broad set of contexts:
- Wound-research models in rodent and porcine skin, where Tβ4 and its fragments appear in re-epithelialisation and dermal-repair assays.
- Cardiac infarct repair models, drawing on Tβ4’s role in cardiac epicardium development and the actin-cytoskeletal remodelling that accompanies post-infarct healing in rodent models.
- Vascular endothelium and angiogenesis, where the LKKTET motif is implicated in endothelial cell migration and tube formation in in-vitro assays.
- Corneal and ocular-surface research, an area where Tβ4 has accumulated a substantial dedicated literature on epithelial repair after chemical or mechanical injury.
- Central-nervous-system regeneration, including stroke and traumatic-brain-injury models in rodents.
- Inflammatory modulation, with effects on macrophage and dendritic-cell behaviour reported across the published in-vitro work.
A useful starting point for anyone reading into the wider literature is Goldstein’s 2005 review, “Thymosin beta-4 and the role of the thymosins in regulating cellular activities”, plus the subsequent body of work from Kleinman and colleagues on the LKKTET motif specifically. The literature is older and more clinically diverse than the BPC-157 corpus and reads as a slow accumulation of cell-biology and tissue-repair observations rather than a single dominant research programme.
The actin-binding mechanism
LKKTET binds G-actin.
Actin inside a cell exists in two interconverting forms: monomeric G-actin and polymerised F-actin. The balance between the two is what drives every cytoskeletal behaviour the cell relies on, including cell migration, shape change, and the lamellipodia that drive wound closure and vascular sprouting.
Thymosin Beta-4 is the most abundant G-actin-sequestering protein in mammalian cells. It binds monomeric G-actin in a 1-to-1 complex and keeps it in a polymerisation-incompetent state until it’s needed. The binding is mediated through the LKKTET motif and the adjacent N-terminal residues, which is exactly the region preserved in the TB-500 fragment.
The downstream consequence in cell-biology terms is that introducing additional Tβ4 or LKKTET-containing fragments shifts the G/F-actin equilibrium and the dynamics of actin filament turnover. Every downstream observation in the wound, cardiac, vascular and CNS literatures traces back to this single core mechanism.
What to look for on the Certificate of Analysis
Our walk-through of how to read a Janoshik HPLC report covers the general structure. For TB-500 specifically there are three things that matter beyond the standard purity check:
1. The COA states the sequence, not just ‘TB-500’
This is the single most important check for this compound. A reputable lab states the exact amino-acid sequence and the molecular weight of the molecule in the vial. A vial labelled simply ‘TB-500 99% purity’ with no sequence, no MW and no MS panel is genuinely ambiguous: you don’t know whether you have the fragment or the full protein.
2. The HPLC chromatogram shows a single dominant peak
Standard reversed-phase HPLC at the appropriate retention time for the stated sequence, purity reported at 99%+ in the analytical summary, and a flat baseline elsewhere. Multiple peaks of comparable height suggest either an incomplete synthesis or a mixed preparation, neither of which is what you want for analytical reference work.
3. Mass-spectrometry matches the stated sequence
Where MS data is included, the observed molecular ion should correspond to the stated sequence. For the 17-residue fragment commonly supplied as TB-500, expect a singly protonated [M+H]+ in the 1700-1800 g/mol range. For the full 43-residue Thymosin Beta-4 protein, expect multiply-charged species adding back to approximately 4963 g/mol. If the MS doesn’t match the claimed sequence on the certificate, the certificate is wrong, the vial contents are wrong, or both.
Storage and handling at your bench
- Refrigerate at 2–8 °C in the original sealed amber-glass vial. TB-500 is stable for 24 months or more in the lyophilised state when kept dry, sealed, and protected from light.
- Reconstitute with bacteriostatic water by adding the water slowly down the inside wall of the vial and gently swirling (not shaking, never vortexing) until the cake fully dissolves. The resulting solution should be clear and colourless.
- Reconstituted shelf life is shorter than the lyophilised form. Published preclinical analytical literature commonly references stability over a window of three to six weeks under refrigeration; consult the specific assay or research method you are running for the exact figure.
- Avoid freeze-thaw cycles on the reconstituted solution. Repeated freezing and thawing is the single most common reason a previously good vial of any reconstituted research peptide drops in measurable activity over time.
Common red flags when sourcing TB-500
Walk-away signals when buying TB-500
- No sequence stated on the COA. Just ‘TB-500’ and a purity percentage. This is the single biggest red flag specific to this compound. Real reference reagent always states the sequence.
- No mass-spectrometry data, or an MS panel that doesn’t reconcile with the stated sequence on the chromatography page.
- Lyophilised cake shown as a heap of loose granules rather than a uniform porous white cake. Freeze-drying done correctly produces a solid puck, not a powder.
- No batch-specific COA, only a generic ‘we test our products’ statement on the website.
- COA carries no verification key, or the key does not resolve on the issuing lab’s public portal.
- Pricing far below the broader market rate. The full 43-residue protein is genuinely expensive to synthesise to 99%+ purity, and a vial priced as if it were a small fragment is probably a small fragment, regardless of what the label says.
- Vial label has no batch number, no fill weight, or no manufacturer identifier.
- Marketed alongside human-use dosing claims or therapeutic statements. TB-500 is supplied as a research reagent only and any therapeutic framing is outside the supply category.
Where this fits in the regenerative-research family
TB-500 sits alongside BPC-157, GHK-Cu and Thymosin Alpha-1 in the regenerative-research category. The chemistries are completely different across the four: TB-500 acts via actin binding, BPC-157 via gastric-body-protective-compound signalling, GHK-Cu via copper-coordination biology, and Thymosin Alpha-1 via immunomodulation. Our side-by-side write-ups cover the trade-offs:
- BPC-157 vs TB-500 – pentadecapeptide vs Thymosin Beta-4 fragment
- GHK-Cu vs BPC-157 – copper tripeptide vs pentadecapeptide (for broader context)
The KLOW research blend in our catalogue includes TB-500 as one of its four components alongside BPC-157, GHK-Cu and KPV. KLOW is a single research-context tool that combines the four; if the work only calls for one of the four, the standalone single-peptide vial is the simpler reference choice.
What we supply
We stock TB-500 as a lyophilised cake in 10mg amber-glass vials, independently HPLC-verified by Janoshik Analytical to 99%+ purity. The Janoshik certificate of analysis ships in the box with every order where one is available for the current batch, and the report is also published on our Purity page for independent reference. The product page with current pricing, the integrated dose calculator, the research-protocol tabs, and the BAC-water option is at /peptides/tb500.html.
Research use only. The compound information described above is drawn from peer-reviewed analytical and preclinical literature and is provided for laboratory and in-vitro research context. Pure Peptides Lab Ltd does not provide therapeutic claims, dosing guidance, administration protocols, or any content relating to human or veterinary use.